Bioidentical Menopausal Hormone Therapy (BMHT) has emerged as a revolutionary approach in the management of menopausal symptoms. This therapy utilizes hormones that are chemically identical to those naturally produced by the human body, hence the term "bioidentical". This concept has been embraced by many patients and healthcare providers alike, as it offers a more personalized approach to hormone therapy.
BMHT is available through both commercially available products and compounding. Compounding involves creating an individualized preparation in response to a healthcare provider’s prescription. This method tailors the medication to the unique needs of an individual patient, offering a level of customization that is not typically available with conventional hormone therapy.
Examples of compounded hormones include Biest (biestrogen) and Triest (triestrogen) preparations. Biest commonly refers to an estrogen preparation based on a ratio of 20% estradiol and 80% estriol on a milligram-per-milligram basis. A similar preparation, Triest, usually contains a ratio of 10% estradiol, 10% estrone, and 80% estriol. Other commonly compounded hormones include dehydroepiandrosterone, pregnenolone, testosterone, and progesterone.
Compounded bioidentical hormones are made by a compounding pharmacist from a healthcare provider’s prescription and are available in various routes of administration, including oral, sublingual, and percutaneous or as implants, injectables, and suppositories. This flexibility in administration routes allows for a more personalized approach to treatment, catering to the individual preferences and needs of each patient.
Scientific data supports the use of BMHT. Steroid hormones, such as estrogen and progesterone, do not require individualized testing as they do not have a narrow therapeutic window. This means that the same dosage can be effective for a wide range of patients, simplifying the treatment process.
The Women's Health Initiative (WHI) findings have led to a shift in the perception of menopausal hormone therapy. The WHI reported that combined hormone therapy did not provide cardioprotection and was associated with an increased risk of incident breast cancer, venous thromboembolism, and stroke. However, these findings have not deterred the exploration and development of safer and more effective alternatives, such as BMHT.
Case Study: Consider a 50-year-old woman experiencing common menopausal symptoms such as sleep disturbances, weight gain, knee and hip pain, hair loss, low libido, and depression. After researching online, she consults with her healthcare provider about BMHT. Based on her symptoms and a salivary hormone assay, her healthcare provider prescribes a customized list of natural hormones. She begins her journey with this personalized form of hormones under the guidance of her healthcare provider, demonstrating the responsible healthcare practices associated with BMHT.
In conclusion, BMHT offers a promising and personalized approach to the treatment of menopausal symptoms. As with any treatment, it's crucial to consult with a healthcare provider before starting a new regimen. BMHT represents a significant step forward in the field of menopausal symptom management, offering hope and relief to countless women worldwide.
1. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004;11:356-67.
2. Drisko JA. “Natural” isomolecular hormone replacement: an evidence-based medicine approach. Int J Pharmaceut Compounding 2000;4:414-20.
3. American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. ACOG Practice Bulletin 28. Washington, DC: ACOG; 2001.
4. U.S. Food and Drug Administration. FDA takes action against compounded menopause hormone therapy drugs. Silver Spring (MD): FDA; 2008.
5. U.S. Food and Drug Administration. Report: limited FDA survey of compounded drug products. Silver Spring (MD): FDA; 2009.
6. Flyckt RL, Liu J, Frasure H, Wekselman K, Buch A, Kingsberg SA. Comparison of salivary versus serum testosterone levels in postmenopausal women receiving transdermal testosterone upplementation versus placebo. Menopause 2009;16:680-8.
